Angelini Ventures' parent company Angelini Industries reports significant growth in FY 2023 consolidated financial statements 7/19/2024 Category: FEATURED IN
Angelini Ventures invests into extended €75.8 million Series C financing round for Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized cancer vaccines 3/21/2024 Category: INVESTMENTS
Inside Angelini Ventures: CEO Paolo di Giorgio discusses innovative investment strategy in Innlifes interview 2/12/2024 Category: FEATURED IN
Avation Medical raises $22M+ to launch closed-loop wearable neuromodulation tech for overactive bladder treatment 2/5/2024 Category: INVESTMENTS
Episode 1 of Stories Behind the Change the first podcast by Angelini Industries spotlights our portfolio company Serenis 2/1/2024 Category: FEATURED IN
COUR Pharmaceuticals Secures $105 Million in Series A financing to advance first-in-class therapies to reprogram the immune system 1/30/2024 Category: INVESTMENTS
Angelini Ventures